View Post

Continuous treatment with abemaciclib leads to sustained and efficient inhibition of breast cancer cell proliferation

In In The News by Barbara Jacoby

By: Impact Journals LLC From: medicalxpress.com Worldwide, breast cancer (BC) is the second most common cancer. Pharmacologically targeting cyclin-dependent kinase 4 and 6 (CDK4 & 6) has proven to be a successful therapeutic approach in patients with estrogen receptor-positive (ER+) breast cancer. Abemaciclib is the first FDA-approved CDK4 & 6 inhibitor (CDK4 & 6i) approved for the adjuvant treatment of …

View Post

Early Stage HER2+ Breast Cancer: Overview of Adjuvant Treatment

In In The News by Barbara Jacoby

By: Andrew D. Seidman, MD, Vijayakrishna Gadi, MD, PhD, Tiffany A. Traina, MD, William J. Gradishar, MD, Stephanie L. Graff, MD From: onclive.com Transcript: Andrew Seidman, MD: Hello, and welcome to this OncLive® Peer Exchange® titled “Updates in the Treatment of HER2+ and HER2-Low Breast Cancer.” I’m Dr Andrew Seidman from Memorial Sloan Kettering Cancer Center in New York [New …

View Post

FDA approves Lynparza for new breast cancer indication

In In The News by Barbara Jacoby

From: healio.com/news The FDA expanded the approval of olaparib to include a new breast cancer indication. The approval applies to use of the agent as adjuvant treatment for patients with germline BRCA-mutated, HER2-negative high-risk early breast cancer who received chemotherapy in the neoadjuvant or adjuvant settings. Olaparib (Lynparza; AstraZeneca, Merck) is a poly(ADP-ribose) polymerase (PARP) inhibitor approved in the United …

View Post

NICE Approves Adjuvant Trastuzumab for HER2-positive Early Breast Cance

In Clinical Studies News by Barbara Jacoby

By: Dawn O’Shea   From: medscape.com The National Institute for Health and Care Excellence (NICE) has approved trastuzumab emtansine as an option for the adjuvant treatment of human epidermal growth factor receptor 2 (HER2)‑positive early breast cancer in adults who have residual invasive disease in the breast or lymph nodes after neoadjuvant taxane-based and HER2‑targeted therapy. Trastuzumab is an adjuvant …